HHHHoward Hughes Holdings Inc.

HHH — Howard Hughes Holdings Inc. — dossier, 2026-09-23

Run in a session on the owner's request, following .claude/skills/stock-sourcing-pipeline/SKILL.md. It covers the name-pass stages of slot names-additions-2026-09-23-1, for HHH only (1913.HK is run in parallel by another session). Model-drafted; nothing here is human-verified. Sourced facts carry the document they were read from; [background] marks background knowledge and [search-summary] marks search-result evidence. Transcript content is paraphrased, never quoted. Private: this directory never reaches dist/.

Industry stages (S0, S4, S6, S7) are in _clusters/cluster-additions-HHH-2026-09-23.md.

Access this run

• threespread.py check: OK — key present (len 46), HTTP 200 from api.3spread.com.
• SEC EDGAR: reachable with the User-Agent in tools/edgar.py; filings saved as text in the session scratch directory.
• Equibles: reachable. 3 calls spent (Q2 2026 transcript, Q1 2026 transcript, short interest).
• ROIC.ai: prices (1 call).
• WebSearch: 2 queries.

§1 — S1 Source

watchlist (owner, 2026-09-23 addition, WATCHLIST_PLAN.md §24). Row added to watchlist.yaml on 2026-09-23 with CIK 1981792 and cluster holding_co. No Tier 0 promotion. No board claim rows. Predecessor issuer for the pre-2023 history: The Howard Hughes Corporation, CIK 1498828 (XBRL companyfacts carries both; the holding-company reorganisation put HHH above it in 2023, and HHC is now the wholly owned real-estate subsidiary and issuer of the senior notes).

§2 — S2 Kill test

Sources: XBRL companyfacts (CIK 1981792, with 2017–2021 continuity from CIK 1498828); FY2025 10-K MD&A for MPC EBT and NOI; Q2 2026 10-Q for H1 2026 and the balance sheet. Q2 diluted count derived as $158.4m / $2.68. 2023's loss and 2024's equity step-down include the Seaport write-downs and the 2024 spin-off of Seaport Entertainment Group [background for the attribution; the 10-Q names the spinoff]. Dashes: not extracted this run.

Revenue is lumpy by construction — condominium closings arrive tower by tower (527 units at The Park Ward Village in Q2 2026 alone lifted Strategic Developments EBT to $126.6m, 10-Q). The steady lines are Operating Assets NOI ($245.5m → $262.0m) and MPC EBT ($349.1m → $476.1m, +36%).

Margins. MPC is the profit engine: Q2 2026 MPC EBT $134.7m on $171m of land sales revenue (10-Q). Operating Assets EBT is negative after depreciation and interest (−$27.4m in 2025, 10-K) — the NOI is real, the property-level leverage absorbs it.

Debt and maturity wall. Carrying debt $5.46bn at 2026-06-30. Corporate senior notes after the February 2026 refinancing: $650m 4.125% due 2029, $650m 4.375% due 2031, $500m 5.875% due 2032, $500m 6.125% due 2034 (10-Q forward-looking list; 8-K 2026-02-17); the $750m 5.375% 2028 notes were redeemed at 100.896 on 2026-02-19 (8-K 2026-02-04). Bridgeland secured notes due 2029: $85m drawn, $515m undrawn. The rest is property-level, mostly non-recourse; at year-end $2.1bn of the $5.1bn was recourse (10-K Item 1A). Near-term wall: none at corporate level before 2029. The company's non-GAAP net debt was $3.28bn at 2025 year-end (10-K; includes JV share, nets cash and MUD/SID receivables) and $2.85bn at 2026-06-30 on the 10-Q's narrower definition — but that $2.85bn nets $1.9bn of cash held at Vantage (10-Q footnote), which is insurance float backing reserves and restricted by the Delaware approval (dividends from the Delaware insurers need prior approval until 2028-06-04). Read net debt ex-Vantage: roughly $4.75bn, computed as $5.46bn gross less the $0.71bn of cash outside Vantage (the 10-Q's $2.65bn less its $1.9bn). Against 2025 Operating Assets NOI plus MPC EBT of ~$0.74bn that is ~6.4x — the leverage of a property company, not of an insurance holding company. ⚠️ Covenant note: "As of June 30, 2026, the Company was not in compliance with certain property-level debt covenants." (10-Q, Debt Compliance); the effect is restricted excess cash at those properties, which the 10-Q says did not affect liquidity.

Share count over five years. Cover-page shares outstanding 55.1m (Feb 2021) → 49.8m (Feb 2023) → 50.4m (Feb 2025) → 59.4m (Jul 2025) → 59.7m (Aug 2026) (XBRL dei; 2026 proxy record date 59,719,462). Buybacks of $81.1m (2021) and $403.9m (2022) shrank it; the 9.0m shares sold to Pershing Square at $100 on 2025-05-05 grew it by 18% (8-K 2025-05-06). Net over five years: +8%. Outstanding dilution: Grandisson's warrants over 1,131,273 shares at $100 (exercisable 2030) and the Series A preferred, which exchanges into the insurance subsidiary, not into HHH common.

FCF. Operating cash flow was negative in 2021 and 2023 and $325–462m in the three other years; H1 2026 +$277.1m on the Park Ward Village closings. Management guides to $2.5–3bn of excess cash over five years from the real estate (both calls, paraphrased; a company target).

Analyst coverage count: J.P. Morgan, Piper Sandler and BMO asked questions in Q1; J.P. Morgan, Piper Sandler and KBW in Q2 (plus individual investors). Four firms on the calls; a formal count was not pulled.

Survives or dies: survives. No corporate maturity before 2029, $2.6bn of cash (of which $1.9bn at Vantage), positive operating cash flow, land that keeps selling. ⚠️ What survives is a leveraged real-estate company funding an insurer: ex-Vantage net debt is ~6.4x the two steady profit lines, and the Vantage cash that makes the consolidated net debt look lower is not available to the parent.

§3 — S3 Filings (gate-minimum)

Read: FY2025 10-K Item 1 (overview, strengths), Item 1A (industry, strategy/Pershing Square and financial risks) and Item 7 (highlights, MPC, net debt); Q2 2026 10-Q Notes 1–4 (AdVantage, Vantage acquisition and purchase-price allocation, Pershing Square, investments), MD&A (overview, highlights, Vantage results, liquidity, insurance-specific considerations), Item 3 (equity price risk), Item 1A (amended and new risk factors); 2026 DEF 14A ownership table and CD&A; 8-Ks listed in the cluster file §0; the S-3ASR cover; the EDGAR filing index for red flags; Q1 and Q2 2026 call transcripts.

The three biggest risks management discloses, in its own words

1. Control by Pershing Square. > "Pershing Square has the ability to influence our policies and operations and its interests may not in all cases be aligned with other stockholders." > — FY2025 10-K, Item 1A, Risks Related to Our Holding Company Strategy and Our Relationship with Pershing Square, first heading

Sized: 46.6% of common (2026 proxy), voting capped at 40% on board-recommended matters and ownership capped at 47% under the standstill (8-K 2025-05-06); Pershing Square also holds the $1.0bn preferred in the insurance holding company and manages Vantage's float (10-Q Note 3).

1. The strategy change and the insurer. > "Our recent shift in business strategy, including the planned acquisition of Vantage, will create additional and different risks than those we face in our existing real estate business." > — FY2025 10-K, Item 1A, same section, second heading

And the 10-Q's new factor on the insurer's history: > "Vantage was founded in late 2020 and accordingly has a relatively short operating history." > — Q2 2026 10-Q, Part II Item 1A, Risks Related to Our Insurance Operations

With, on the asset side, the new investment-portfolio risk factor's phrase that "adverse investment results may coincide with underwriting losses" (same Item 1A).

1. Housing. > "A downturn in the housing market or decline in general economic conditions could adversely affect our business, financial condition, and operations." > — FY2025 10-K, Item 1A, Risks Related to Our Industry, Market, and Customers, second heading

Fourth, because the leverage is a property company's:

"We have a substantial amount of indebtedness, a significant portion of which will mature in the coming years." — FY2025 10-K, Item 1A, Financial Risks (restated in the Q2 2026 10-Q)

Latest-quarter delta (Q2 2026 10-Q MD&A)

• Net income to common $158.4m (Q2 2025: −$12.1m): 527 condo closings at The Park Ward Village, $51.8m gain on two Woodlands multifamily sales, MPC EBT $134.7m (+32%), less a $20.8m pre-tax loss at Vantage in its 26-day stub (a $38.3m investment loss, mostly $36.0m unrealised on the new equity sleeve, and $20.2m of VOBA amortisation).
• Vantage stub: GWP $156.1m, NWP $107.2m, NEP $97.2m; loss ratio 56.8%, expense ratio 38.4%, combined 95.2%, which the 10-Q says is not representative.
• Balance sheet: total assets $10.64bn → $15.91bn; claim reserves $2.12bn; unearned premium $1.41bn; goodwill $282.2m and intangibles $586.4m (of which VOBA $304m, 90% amortised in year one — a drag on reported insurance earnings through mid-2027); mezzanine preferred $995.8m.
• Liquidity: $2.6bn cash including Vantage; $970.3m undrawn development commitments.
• No 10b5-1 plan adopted or terminated by any director or officer in the quarter (10-Q Item 5).

Capital actions on file

• Pershing Square common purchase: 9.0m shares at $100, $900m, 2025-05-05, with the services, shareholder, standstill and registration-rights agreements (8-K 2025-05-06).
• Pershing Square advisory fee: "The Company will pay Pershing Square a quarterly base fee of $3,750,000 and a quarterly variable fee equal to 0.375% of the excess value of the quarter-end stock price of the Common Stock minus the reference price of $66.1453, multiplied by existing share count of 59,393,938 shares" (8-K 2025-05-06). Base $15m a year, PCE-indexed; the variable fee is ~$0 at $66 and ~$30m a year at $100 (computed). Fees recognised: $7.6m in H1 2026 (10-Q Note 3). Ten-year initial term with ten-year renewals; a change-of-control termination pays a make-whole of the remaining fees.
• Series A non-voting exchangeable perpetual preferred: 140,000 shares to Pershing Square Holdings, Ltd. for $1.0bn, 2026-06-04 (8-K 2026-06-05; Form 4 of 2026-06-08 at $7,142.86 a share). Dividends only if the disinterested directors declare them, and capped: "Such declared dividends may not exceed the pro rata cash dividends or distributions actually received by the Company from Vantage (through Buyer)." Exchange into insurance-holding units from 60 days after the seventh fiscal year (FY2032); HHH call 60–90 days after each of the first seven fiscal year-ends at the greater of 4% accretion and 1.5x tangible book; mandatory repurchase offer on a change of control; 10% default dividend if a required repurchase is not paid.
• Notes refinancing: $1.0bn of 2032/2034 notes issued 2026-02-17 to redeem the $750m 2028 notes; the balance funded the Vantage closing (8-K 2026-02-04, 2026-02-17).
• Grandisson warrants: $10m paid for warrants over 1,131,273 shares at $100, exercisable 2030-04-20 (8-K 2026-04-21).
• Universal shelf: S-3ASR filed 2026-08-14 — debt, common, preferred, warrants, units, amount unlimited by construction. No takedown. Filed eight days after the executive chairman said issuing equity near current prices would not be intelligent (Q2 call, paraphrased); a WKSI shelf is also routine housekeeping, and Pershing Square's subscription rights attach to any common issuance.
• Buyback: the March 2022 $250m authorisation, $235.0m used in 2022, remains open; no purchases since (10-Q Note on common stock).

Proxy skim (2026 DEF 14A, meeting 2026-09-30)

• Insider ownership: all directors and executive officers as a group (17 persons) 28,460,906 shares, 47.7% — of which Ackman's attributed Pershing Square holding is 27,852,064 (46.6%). Excluding Pershing Square, insiders own ~608,842 shares, ~1.0%. CEO David O'Reilly 227,439.
• What the bonus is paid on: 75% on Operating Assets NOI ($262.0m vs $247.0m target, 106%), MPC EBT ($476.1m vs $472.4m, 101%), condominium profit and corporate cash G&A; 25% individual. CEO 2025: $1.0m salary, $2.1m bonus, $4.68m long-term equity. Nothing in the 2025 scorecard measures Vantage, book value per share or return on capital — the metrics are the old real-estate ones, and the MPC EBT target was set only $3.7m below the result.
• Executive Chairman and CIO are Pershing Square's Ackman and Israel, paid through the services agreement rather than by HHH (inferred from the structure; the proxy was not read for their line).
• Routine meeting: directors, say-on-pay, KPMG ratification. KPMG auditor "since 2022" (10-K auditor's report); the predecessor changed auditors by 8-K Item 4.01 in May 2022.

Insider pattern (3spread insiders --days 365 --limit 200, 54 filings; Form 4 XML read directly)

Plus many tax-withholding (F) rows on 2025-12-31 and 2026-02-03/05 at $79.77–$80.04, and director grants on 2026-06-19. The Pershing Square "J" row is a transfer between its own vehicles for a special redemption of limited-partner interests (Form 4 footnote), not a sale. Pattern: immaterial. Two small open-market purchases, four small sales, no pattern either way. Form 144s (2025-11-26 through 2026-08-17, six) were not opened.

Red-flag sweep

• No NT 10-K / NT 10-Q for either CIK since 2011; no 10-Q/A. Two 10-K/As, both Part III only because the proxy came late (the 2026 one says so on its face).
• SEC comment-letter correspondence: last CORRESP/UPLOAD 2017 (predecessor); none on HHH.
• Auditor change: May 2022 (8-K Item 4.01, predecessor) to KPMG.
• Executive changes: Ben Hakim (Pershing Square) left the board 2026-05-07 and Marc Grandisson took the Pershing seat (8-K 2026-04-21); L. Jay Cross (President) retired 2025-09-16 with $4.57m of severance (2026 proxy); the 10-Q says Vantage has had several senior leadership changes since announcement. Its CEO-designate from Arch is under a non-compete until about June 2027 (Q2 call, paraphrased).
• Property-level covenant non-compliance (above).
• Going concern: not applicable on these numbers; not searched on Equibles to save budget.

Transcripts — Q1 2026 (2026-05-08) and Q2 2026 (2026-08-06), Equibles, read Q&A-first

Guidance and commentary changes (prepared remarks):

• Q1: annual guidance withdrawn because of the pending Vantage deal; replaced by new KPIs (MPC residual land value, operating-asset adjusted maintenance free cash flow, condo remaining profit). The CEO said Q1 land sales and MPC EBT were ahead of plan. The CIO put the company's conservative value at about $104 a share and a 2030 target at about $211 (a company estimate). Excess cash from real estate over five years: $2.5–3bn.
• Q2: Vantage-standalone Q2 combined ratio 101.6% ($18m cat losses tied to the Iran conflict, $19m adverse prior-year development largely in a discontinued transaction-liability line); H1 96.1%; current-year ex-cat 90.9% H1. A.M. Best affirmed A- with positive outlook; S&P's action described as a group-methodology result. Equity sleeve ~33% at quarter-end, ~40% five weeks later, target north of 50%; it was down ~3% at quarter-end and up 4–5% a month later per the CIO. New Vantage leadership: Grandisson as executive chair, an Arch co-president as CEO-designate. The real estate business will be pruned and partly financed with third-party capital; the stated direction is to become disproportionately an insurance holding company. Equity issuance at current prices ruled out by the executive chairman.

What the analysts asked about (by topic):

• Pershing Square's capacity and commitment — both calls (J.P. Morgan in Q1 on the Pershing Square listings; J.P. Morgan in Q2 on further support). Answered: Pershing is capped at 47% and calls HHH a permanent holding; further capital comes from real-estate monetisation.
• The value estimate — Q1 (Piper Sandler).
• Monetisation of real estate and competitive position inside the MPCs — Q1 (J.P. Morgan), Q2 (Piper Sandler).
• Data centres or other uses for the Phoenix land — Q1 (Piper Sandler).
• Whether the new KPIs reward holding land rather than selling it — Q1 (BMO).
• The Vantage investment portfolio and claims liquidity — Q2 (Piper Sandler).
• Underwriting targets, the cycle, reinsurance growth — Q2 (KBW, Meyer Shields). The equity return is not in the underwriting ROE target, per Grandisson — answered directly.
• Capital allocation between real estate and Vantage — Q1 (BMO), Q2 (an individual investor).

Dodges:

• Q1 2026 · value estimate down from $118 to $104 · Alexander Goldfarb (Piper Sandler). Asked whether the move from the previously disclosed $118 to $104 was the dilution from the $100 issue. The answer described why the method is conservative and said there is some dilution; it did not bridge the $14. Locator: Equibles Q1 FY2026 transcript, Goldfarb's second question.
• Q1 2026 · which real-estate investments are deferred to fund Vantage · John Kim (BMO). Asked what investments in the MPC business are now being deferred or removed. The answer gave the counterfactual that West Phoenix would have been $600m more into Vantage and the higher ROE of insurance; no project was named. Locator: Q1 transcript, Kim's second question.
• Q2 2026 · the hurdle a dollar must clear · individual investor (name garbled in the machine transcript). Asked what an opportunity has to clear to win capital now that real estate and Vantage compete. The answer said every incremental dollar goes to Vantage and described the equity market; no hurdle rate or comparison was given. Locator: Equibles Q2 FY2026 transcript, the individual-investor exchange after KBW.

Not asked, recorded: nobody asked about the S&P downgrade and withdrawal, the $19m of adverse development, or the 1.5x-book call price on the preferred. The chair's own description of the S&P action (group methodology) did not say "downgrade" or "withdrawn"; that is framing, not a dodge, because no question was put.

Thread: capital allocation between the land and the insurer was not answered with a number in Q1 or Q2 (one sell-side, one retail asker). Two quarters — flagged in the scorecard ⚠️ line and backed by an S9 trigger (the segment capital-contribution disclosure).

§4 — S5 Ownership

13F at 2026-06-30 (threespread.py holders HHH): Pershing Square Inc. 27,852,064 sh ($1,991.1m, i.e. $71.49 at 2026-06-30); Wells Fargo 1,807,568 (−1,253,188); BlackRock 1,619,333 (+139,898); Long Focus Capital 733,695; Flat Footed 620,418 (+405,130); Gotham 598,252 (+303,245); State Street 585,843; River Road 492,052; Citadel 469,862 (+307,962); Susquehanna 399,565; Jane Street 341,564.

• ⚠️ Ingestion incomplete: 195 filers for Q2 against 288 for Q1. Vanguard (3.30m + 3.01m at Q1), Dimensional (2.82m), American Century (1.24m), Donald Smith (1.04m), Geode, Franklin, Morgan Stanley have no Q2 13F ingested yet — not exits.
• ⚠️ The tool's Exited since prior quarter line for Pershing Square Capital Management, L.P. (18,852,064 sh) is a change of reporting entity (the fund holding now reported under Pershing Square Inc., whose row shows +18,852,064), not an exit — the total is 27,852,064 on both the 13F and the proxy.
• ⚠️⚠️ The Sixth Street row (190,306 sh, "NEW") is not a holding. It carries exactly Charles Schwab Investment Management's share count; 3spread flags the duplicate. Same filing defect as ACGL/dossier-2026-09-22.md §5, NLY and KNSL. Not carried.

13D/G census (threespread.py owners HHH): Pershing Square's Schedule 13D/As on each capital event (2025-05-07, 2025-08-07, 2025-12-19, 2026-04-29, 2026-06-08); passive 13G/13G-As otherwise (latest 2026-07-31 for 2026-06-30). No other 13D.

Short interest: 3,544,116 shares at 2026-08-31 (FINRA via Equibles), up from 2,635,919 at 2026-06-30 — five consecutive increases; 8.3 days to cover. 5.9% of shares outstanding, 11.1% of the float outside Pershing Square. An Equibles model estimate for 2026-09-15 (~3.65m, low confidence) is not a FINRA figure and is not relied on.

Shelf / ATM / buyback: unlimited universal S-3ASR on file since 2026-08-14 (no takedown); no ATM found; $15m of the 2022 $250m buyback authorisation unused and dormant. Absence of an ATM in the filings read is not proof that none exists.

Who is on the other side: Pershing Square (46.6%, capped at 47%, 40% voting cap, a permanent holder by its own statement), index money, a handful of value managers, and multi-strategy and market-making desks that added in Q2 (Citadel, Jane Street, Susquehanna, HRT). Insiders outside Pershing own ~1%. The shorts hold 11% of the non-Pershing float.

§5 — S8 Valuation & sizing (model; buy price and size ⏳ OPEN (user))

HHH has no stable earnings line to multiply, and the company itself has moved to NAV-style KPIs. The model is book value per share at mid-2028 × a price-to-book multiple, with book built up from the three parts.

Inputs: BVPS $66.39 at 2026-06-30 (common equity $3,960.4m / 59,657,062 shares, 10-Q balance sheet); tangible $51.83; H1 2026 net income to common $166.6m; equity sensitivity ±$107.8m per 10% (10-Q Item 3). The P/B multiples are assumptions. The base-case +18% has no dividend on top (HHH pays none). Not used: the company's $104 "conservative" value and $211 2030 figure (Q1 call), which rest on a land residual value and a deck not read here.

Proposed buy price ⏳ OPEN (user): at or below 0.85x the latest reported BVPS (~$56 on the 2026-06-30 book), and only once the FY2026 10-K shows the first Vantage loss-development table without adverse development. At today's 1.00x the market is paying full book for a structure whose upside above 1.5x tangible book in the insurer is shared with the preferred.

Proposed size ⏳ OPEN (user): liquidity is adequate but not deep — ADV $41.6m and only ~31.9m shares outside Pershing Square. A position building at ≤5% of ADV is ~$2m a day. The binding constraint is correlation: at 40–50% equities, Vantage's book tracks Pershing Square's portfolio, so size HHH as part of any Pershing Square exposure (PSH, PSUS) the owner already has, not beside it.

§6 — S9 Monitoring

• Next earnings: ~2026-11-05 to 2026-11-10 (DERIVED from cadence, not from a calendar): Q3 2025 was released 2025-11-10, Q1 2026 on 2026-05-07, Q2 2026 on 2026-08-05; the call follows the next morning. The annual meeting is 2026-09-30 (8-K/A 2026-08-11), routine items only.
• Filing feed: Tier 0 EDGAR sweep, cik: 1981792 on the watchlist row. Pershing Square's 13D/As are filed under HHH's CIK and will surface there too.
• Leading indicator between quarters: Pershing Square's own published portfolio performance [background: PSH publishes NAV weekly] — the CIO said the Vantage sleeve holds largely the same names, so it marks Vantage's book before HHH reports. Second: Summerlin new-home sales and superpad pricing in the MPC quarterly supplemental.
• Trigger that converts it to a buy: price ≤0.85x latest reported BVPS and the FY2026 10-K's first Vantage loss-development table shows no adverse aggregate development and A.M. Best still A- (positive or stable).
• Thread trigger (from the dodge log): the Q3 10-Q or FY2026 10-K disclosing the capital contributed to Vantage and the real-estate development spend side by side. If capital keeps moving to Vantage with no stated hurdle, treat the allocation question as a kill-criterion candidate.
• Trigger that kills it: any of the five kill criteria in the cluster file §5.